Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | LIPE | Q05469 | 5/20 | 0.37 |
| ▸ | BCHE | P06276 | 4/20 | 0.37 |
| ▸ | ACHE | P22303 | 3/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.35 |
| ▸ | XPO1 | O14980 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL462380 | 0.88 | MAP4K4 (0.38) | MAP4K4LIPEBCHEACHESLC6A7 | |
| SCHEMBL425860 | 0.79 | ALDH1A1 (0.46) | LIPEBCHEACHEGABRA5SLC6A7 | |
| SCHEMBL425576 | 0.79 | LIPE (0.56) | LIPEBCHEPOLBHPGD | |
| SCHEMBL425673 | 0.74 | POLB (0.51) | LIPEBCHEPOLBHPGD | |
| SCHEMBL425835 | 0.74 | AKR1C3 (0.54) | POLBHPGD | |
| SCHEMBL427456 | 0.73 | SCN5A (0.51) | LIPEBCHEACHEPOLB | |
| SCHEMBL425856 | 0.67 | CNR2 (0.39) | LIPEBCHEACHEXPO1POLB | |
| SCHEMBL427298 | 0.65 | TSHR (0.51) | HPGD | |
| SCHEMBL427271 | 0.65 | LIPE (0.58) | LIPEACHEXPO1 | |
| SCHEMBL425711 | 0.64 | AKR1C3 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| WO-2010074588-A2 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | BRD4 1155/4885MAP4K4 3117/4885LIPE 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.